FDA Says Product Availability Doesn’t Guarantee Safety or Effectiveness in Warning Against Tianeptine
FDA says tianeptine is often referred to as “gas station heroin” and despite its availability at shops, stores, gas stations & online retailers, poses serious health risks, including death.
In a press advisory distributed Thursday, — and which this reporter also received — the U.S. Food and Drug Administration (FDA) cautioned that consumers may wrongly assume widely available substances are both effective and harmless. The notice highlights a growing trend involving tianeptine — often referred to as “gas station heroin” — which, despite its commercial presence in gas station marts, vape shops, stores & with online retailers, poses serious health risks, including death.
According to the communication, tianeptine is not approved by FDA for any therapeutic application. Yet, the compound can be purchased at gas stations, convenience stores, vape shops and via internet vendors under names such as Tianaa, Zaza, Neptune’s Fix, Pegasus and TD Red. Unregulated use has been linked to severe adverse outcomes, including agitation, confusion, respiratory distress and even fatalities.
The agency’s message emphasized that market availability does not equate to safety or effectiveness. It urged health care professionals to advise patients against consuming any tianeptine-containing products, regardless of marketing claims that they might treat ailments like depression, anxiety, pain or opioid withdrawal.
In a letter dated May 8, 2025, FDA Commissioner of Food and Drugs Martin A. Makary, M.D., M.P.H., described an alarming uptick in reports of harm among primarily younger users. He noted that tianeptine works by altering certain brain chemicals that regulate mood and pain (glutamate) and binding to opioid receptors — fully activating the main (“mu”) ones and more weakly the secondary (“delta”) ones — producing effects similar to opioids. He also said that doses far exceeding those approved abroad — ranging from 50 mg to 10,000 mg daily — have been documented in US case reports.
The commissioner’s correspondence also reviewed the regulatory gaps: tianeptine remains unscheduled under US controlled substances law, is not recognized as a safe food ingredient and fails to qualify as a dietary supplement. Despite these facts, it is marketed as a “research chemical” or “nootropic,” leading consumers to underestimate its dangers.
The FDA official outlined previous interventions, including warning letters to distributors and import alerts targeting shipments of illicit tianeptine. He cited cases of illnesses reported in New Jersey last year, involving the product “Neptune’s Fix,” which combined tianeptine with synthetic cannabinoids and resulted in multiple hospitalizations and deaths from complications such as hypotension, prolonged QT interval and seizures.
The agency’s guidance for clinicians includes encouraging evidence-based treatments for psychiatric and pain disorders, facilitating access to approved medications — such as naloxone for overdose reversal — and reporting any suspected tianeptine-related adverse events via FDA’s MedWatch, the agency’s safety information and adverse event reporting program. Providers are asked to supply detailed product information and, if possible, photographs of packaging to aid in FDA investigations.
By underscoring the disconnect between a product’s retail ubiquity and its pharmacological safety profile, the FDA hopes to curb the rising misuse of tianeptine and protect public health, particularly among impressionable youth.
About the author:
The writer is the founder and CEO of US and Global News. In a past life, he proofread, fact-checked, edited & SEO-optimized news stories for a San Francisco-based news outlet for about four years, a San Jose-based blockchain news outlet for about five years (for whom he also reviewed and published an interview with a former Obama administration director for cybersecurity legislation and policy for the National Security Council) and for a New York-based fitness news website for one year and eight months. He can be reached at tabish@usandglobal.com and followed on X @TabishFaraz1
About US and Global News
US and Global News is an independent online news service reporting stories from the United States and rest of the world in five categories namely US Politics, World Affairs, Business, Science and Technology, and Entertainment. We aim for the highest journalistic standards and hope to become one of your primary sources for news in the categories we cover. Sometimes, we are even able to be the first to publish news of global importance. One news report that we published - about the World Health Organization being aware of the asymptomatic transmission of COVID-19 - over a year ago, back on February 1st 2020 to be exact, was referenced in a COVID-19 scientific research paper also published by one of Australia’s leading public research universities, Monash University. By subscribing to our newsletter, you also get to read news that we publish only for our newsletter subscribers. Maybe someday (hopefully often), we will be able to report something of US and/or global importance first in our newsletter too (we are already US and Global News!). Moreover, the New York Times provided exclusive comments for our story on then-US President-elect Donald Trump demanding an apology from them and a past, another-platform article was liked on social media by a division of US defense contractor General Dynamics.